Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network.
Adolescent
Adult
Age of Onset
Amyloidosis
Child
Child, Preschool
Colchicine
/ therapeutic use
Exanthema
/ drug therapy
Eye Diseases
/ drug therapy
Female
Fever
/ drug therapy
Humans
Joint Diseases
/ drug therapy
Male
Middle Aged
Mutation
Myalgia
/ drug therapy
Phenotype
Receptors, Tumor Necrosis Factor
/ metabolism
Retrospective Studies
Risk
Syndrome
Young Adult
Journal
Mediators of inflammation
ISSN: 1466-1861
Titre abrégé: Mediators Inflamm
Pays: United States
ID NLM: 9209001
Informations de publication
Date de publication:
2020
2020
Historique:
received:
01
02
2020
revised:
27
04
2020
accepted:
28
04
2020
entrez:
23
6
2020
pubmed:
23
6
2020
medline:
10
7
2021
Statut:
epublish
Résumé
To analyze the potential role of colchicine monotherapy in patients with tumor necrosis factor receptor associated periodic syndrome (TRAPS) in terms of control of clinical and laboratory manifestations. Patients with TRAPS treated with colchicine monotherapy were retrospectively enrolled; demographic, clinical and therapeutic data were collected and statistically analysed after having clustered patients according to different times at disease onset, penetrance of mutations, dosage of colchicine, and different disease manifestations. 24 patients (14 males; 15 with pediatric disease onset) treated with colchicine monotherapy were enrolled. Colchicine resulted in a complete response in 3 (12.5%) cases, partial response in 14 (58.3%) patients, and lack of response in 7 (29.2%) patients. There were not significant differences in colchicine response between pediatric and adult disease onset ( Colchicine monotherapy is useful in a low percentage of TRAPS patients; nevertheless, it could be attempted in patients with milder phenotypes and at a lower risk of developing reactive amyloidosis.
Identifiants
pubmed: 32565720
doi: 10.1155/2020/1936960
pmc: PMC7273368
doi:
Substances chimiques
Receptors, Tumor Necrosis Factor
0
Colchicine
SML2Y3J35T
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1936960Informations de copyright
Copyright © 2020 Antonio Vitale et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Ann Rheum Dis. 2006 Sep;65(9):1158-62
pubmed: 16569687
Arthritis Rheum. 2002 Aug;46(8):2181-8
pubmed: 12209523
Front Immunol. 2017 Aug 24;8:1018
pubmed: 28970828
Ann Rheum Dis. 2017 Jan;76(1):173-178
pubmed: 27269295
Eur J Med Genet. 2020 Apr;63(4):103780
pubmed: 31586650
Ann Rheum Dis. 2013 May;72(5):678-85
pubmed: 22753383
Clin Pediatr (Phila). 2004 Sep;43(7):605-8
pubmed: 15378145
J Eur Acad Dermatol Venereol. 2014 Mar;28(3):338-47
pubmed: 23441863
Front Immunol. 2017 Mar 27;8:299
pubmed: 28396659
Clin Rheumatol. 2014 Sep;33(9):1197-207
pubmed: 24935411
N Engl J Med. 2018 May 17;378(20):1908-1919
pubmed: 29768139
Semin Arthritis Rheum. 2014 Jun;43(6):818-23
pubmed: 24393624
N Engl J Med. 1986 Apr 17;314(16):1001-5
pubmed: 3515182
Rheumatology (Oxford). 2003 Feb;42(2):235-9
pubmed: 12595616
Ann Rheum Dis. 2019 Aug;78(8):1025-1032
pubmed: 31018962
Pediatr Nephrol. 2003 Jun;18(6):521-6
pubmed: 12698329
Arthritis Rheum. 2011 Apr;63(4):1141-50
pubmed: 21225694
Lancet. 1990 May 5;335(8697):1078-80
pubmed: 1970380